PRNewsWire
27 Sept 2026, 15:15 UTC · 6h ago
Verdict
Headline takes no side. We score ARAY +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Accuray entered into agreements with Samsung NeuroLogica to integrate advanced volumetric imaging capabilities into the CyberKnife platform.
Newannounced today, Sep 27, 2026
So whatEnhanced imaging capabilities for lung and prostate cancers could drive higher system adoption and ASPs in FY2027.
More positive than 78% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The Royal Marsden NHS Foundation Trust is the first center worldwide to participate in the Accuray–Samsung NeuroLogica collaboration.
Newannounced today, Sep 27, 2026
More positive than 53% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company announced a strategic collaboration to enhance its CyberKnife platform with advanced volumetric imaging capabilities.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
5h ago
—
ARAY hasn't traded since this ran. Last close $0.2151 (Sep 25); the reaction starts at the next open.
ARAY chart →
